CD8A and adenocarcinoma: They revealed in an experimental adenocarcinoma model that therapeutic blockade of the PD-L1–PD-1 axis evoked dominant immune cell activation within the TDLN but not in the non-TDLN, resulting in homing, activation, and proliferation of CD8+ T cells in the tumor microenvironment of the adenocarcinomas.